United States· US:69452-223_3d338656-9665-cc13-e063-6294a90ab433
Rufinamide
A rufinamide product containing rufinamide, registered in United States by Bionpharma Inc.. The same ATC class is registered in 17 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Rufinamide is registered in 17 of 19 countries.
Countries holding a registration under ATC N03AF03 (rufinamide), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 10 of them publish a price we can compare per daily dose
Rufinamide · ATC N03AF03
17 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of rufinamide costs, country by country.
Normalised to the WHO defined daily dose (1.4 g), the median price runs from $7.83 in Switzerland to $12.24 in Italy — a ×1.6 gap.
- 3 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Rufinamide · price per daily dose (1.4 g)
USD · FX 28 Sept 2026
- IT Italy$12.24
- FR France$8.57
- CH Switzerland$7.83
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- RUFINAMIDE
- Manufacturer
- Bionpharma Inc.
- Country
- United States (US)
- ATC code
- N03AF03
- ATC class
- Rufinamide
- Defined daily dose
- 1.4 g, O
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 2
- ndc1169452223841 BOTTLE in 1 CARTON (69452-223-84) / 460 mL in 1 BOTTLE
- ndc1169452-223-84
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
238 interactions on record for rufinamide.
Graded by severity as the source publishes them — 232 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Rufinamide · interactions on record
238 records
- 232 moderate
- 6 minor
Most severe, free to view
- MetoclopramideA03FA01moderate
- OndansetronA04AA01moderate
- GranisetronA04AA02moderate
- ThiethylperazinA04AB03moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Rufinamide in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaINOVELONEisai GmbH, Frankfurt am Main
- SpainINOVELON 40 mg/ml SUSPENSION ORALEisai Gmbh
- FinlandInovelonEisai GmbH
- FranceINOVELON 40 mg/ml, suspension buvableEISAI (ROYAUME-UNI)
- BelgiumInovelon 40 mg/mlEisai
- NetherlandsInovelon 40 mg/ ml, suspensie voor oraal gebruikEisai GmbH
- NorwayInovelonEisai GmbH
- PolandInovelonEisai GmbH
Authorised across Europe · EMA
The same active substance is authorised in 6 EEA countries. Names it is sold under:
- Germany · Rufinamid Actrevo, Rufinamid Micro Labs
- France · Rufinamide Actrevo, Rufinamide Medipha
- United Kingdom (Northern Ireland) · Rufinamide, Rufinamide Brown & Burk
- Iceland · Inovelon
- Liechtenstein · Inovelon
- Norway · Inovelon
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/db1472d3-34fe-46ae-a700-52a1ad0978f7 GET /v1/drugs/db1472d3-34fe-46ae-a700-52a1ad0978f7?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"source": "ndc",
"strength": "40",
"substance": "RUFINAMIDE",
"productndc": "69452-223",
"dosage_form": "SUSPENSION",
"dea_schedule": null,
"strength_unit": "mg/mL",
"application_number": "ANDA211388",
"marketing_category": "ANDA"
}See everything about rufinamide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.